Kristina (Kris) Bieker-Brady, PhD focuses her practice on strategic patent portfolio development for early stage companies and the handling of intellectual property matters for companies and investors during financings, public offerings, mergers and strategic partnerships. She works to build and preserve layered exclusivity profiles that are structured to peak in strength during the critical periods of a product’s branded commercial sales life. According to IAM Patent 1000, Kris “steps in when the opportunity to monetise a right arises.”
She represents private- and public-side biotech, pharmaceutical and medical device companies and advises clients on matters relating to patent prosecution, including patentability, non-infringement and invalidity opinions, licensing, joint development agreements and patent enforcement. Additionally, she performs IP due diligence on potential investments for some of the top venture capital firms and serial entrepreneurs in the world, some with whom her relationships span a period of more than 15 years. She has been described by clients as having “the commercial savvy and interpersonal skills to quickly ink lucrative licensing contracts with even the most recalcitrant third parties.”
Kris’ experience encompasses cellular immunotherapies; gene therapy; nano and viral systems for oncolytic, gene therapy and vaccine indications; preventative medicine; treatments for devastating neurological and other tissue injuries; treatments—and more critically cures—for developmental and progressive neurological diseases such as autism, ALS and Alzheimer’s.
Prior to joining McDermott, Kris spent 22 years as a co-founder of an IP boutique dedicated to life sciences patent prosecution, serving as a managing partner for the last eight years.
During her academic career, Kris conducted cell biology, genetics and neurobiology research using molecular biology and biochemistry techniques. Select first-author research and review articles have been published in Cell, EMBO Journal, Proceedings of the National Academy of Sciences, Genomics and Trends in Genetics.
*Matter handled prior to joining McDermott.